Grant ID DP200033
Awarded On February 19, 2020
Title Development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor- derived HSP70 to Dendritic Cells
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization Asylia Therapeutics
Principal Investigator/Program Director Richard Jones
Cancer Sites Breast, Myeloma, Pancreas
Contracted Amount $3,000,000
Lay Summary

Immunotherapy is making a meaningful impact on clinical outcomes but only a small fraction of patients achieve durable benefits because cancer can become invisible to the body’s immune system. Our team is developing a novel antibody to Heat shock protein (HSP)-70 created at MD Anderson that works by increasing the ability of dendritic cells, which are key to starting immune reactions, to better recognize the presence of cancer cells. As a result, T-cells become activated to kill cancer cells, and our studies show that this antibody, known as ASY-77A, is active against models of solid tumors such as breast, colon cancer, and melanoma, and against blood-related cancers like multiple myeloma. W...

Read More